ELSEVIER

Journal of Affective Disorders 65 (2001) 323–325

JOURNAL OF AFFECTIVE DISORDERS

www.elsevier.com/locate/jad

Author index

Adinoff, B., see Sherwood Brown, E. (65) 105
Agosti, V. and Stewart, J.W.
Atypical and non-atypical subtypes of depression: comparison of social functioning, symptoms, course of illness, co-morbidity and demographic features (65) 75
Alcorta, P., see Elizagarate, E. (65) 55
Alda, M., Keller, D., Grof, E., Turecki, G., Cavazzoni, P., Duffy, A., Rouleau, G.A., Grof, P. and Young, L.T.
Is lithium response related to G_{α} levels in transformed lymphoblasts from subjects with bipolar disorder? (65) 117
Alonso, I., see Elizagarate, E. (65) 55

Bakish, D., see Du, L. (65) 37
Bauer, M.S., Kirk, G.F., Gavin, C. and Williford, W.O.
Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study (65) 231
Beekman, A.T.F., Deeg, D.J.H., Geerlings, S.W., Schoevers, R.A., Smit, J.H. and Van Tilburg, W.
Emergence and persistence of late life depression: a 3-year follow-up of the Longitudinal Aging Study Amsterdam (65) 131
Beekman, A.T.F., see Van den Berg, M.D. (65) 19
Begley, A., see Dew, M.A. (65) 155
Benazzi, F.
Atypical depression with hypomanic symptoms (65) 179
Bergiannaki, J.-D., see Paparrigopoulos, T. (65) 307
Bertelsen, A., see Pedersen, S.H. (65) 191
Bieling, P.J., see Patelis-Siotis, I. (65) 145
Bouhuys, A.L., see Van den Berg, M.D. (65) 19
Boulanger, B., see Demyttenaere, K. (65) 243
Brilman, E.I., see Van den Berg, M.D. (65) 19
Brink, P.A., see Niehaus, D.J.H. (65) 61
Brody, J.F.
Evolutionary recasting: ADHD, mania and its variants (65) 197
Burns, P., see Tohen, M. (65) 85
Butti, G., see Rossi, A. (65) 3

Cacciani, P., see Turrina, C. (65) 45
Castelli, F., see Turrina, C. (65) 45
Cavazzoni, P., see Alda, M. (65) 117
Cazzaro, M., see Fava, G.A. (65) 185
Corfield, V.A., see Niehaus, D.J.H. (65) 61
Cortes, J., see Elizagarate, E. (65) 55

PII: S0165-0327(01)00381-0

Couvée, J., see Dingemans, A.E. (65) 123
Cox, B.J., Enns, M.W. and Larsen, D.K.
The continuity of depression symptoms: Use of cluster analysis for profile identification in patient and student samples (65) 67
Cox, L.C., see Patelis-Siotis, I. (65) 145

Dafni, U., see Paparrigopoulos, T. (65) 307
DeBattista, C., see Koran, L.M. (65) 27
Deeg, D.J.H., see Beekman, A.T.F. (65) 131
Delsemme, M.-H., see Demyttenaere, K. (65) 243
Demyttenaere, K., Mesters, P., Boulanger, B., Dewe, W., Delsemme, M.-H., Gregoire, J. and Van Ganse, E.
Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine (65) 243
Dew, M.A., Reynolds, C.F., Mulsant, B., Frank, E., Houck, P.R., Mazumdar, S., Begley, A. and Kupfer, D.J.
Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well (65) 155
Dewe, W., see Demyttenaere, K. (65) 243
Di Cicco, L., see Rossi, A. (65) 3
Dingemans, A.E., Van Vliet, I.M., Couvée, J. and Westenberg, H.G.
Characteristics of patients with social phobia and their treatment in specialized clinics for anxiety disorders in the Netherlands (65) 123
Du, L., Bakish, D. and Hrdina, P.D.
Tryptophan hydroxylase gene 218A/C polymorphism is associated with somatic anxiety in major depressive disorder (65) 37
du Toit, P.L., see Niehaus, D.J.H. (65) 61
Duffy, A., see Alda, M. (65) 117

Elizagarate, E., Cortes, J., Gonzalez Pinto, A., Gutierrez, M., Alonso, I., Alcorta, P., Ramirez, M., Pz de Heredia, J.L. and Figuerido, J.L.
Study of the influence of electroconvulsive therapy on the regional cerebral blood flow by HMPAO-SPECT (65) 55
Emsley, R.A., see Niehaus, D.J.H. (65) 61
Enns, M.W., see Cox, B.J. (65) 67

Fava, G.A., Rafanelli, C., Ottolini, F., Ruini, C., Cazzaro, M. and Grandi, S.
Psychological well-being and residual symptoms in remitted patients with panic disorder and agoraphobia (65) 185

Figueridо, J.L., see Elizagarate, E. (65) 55
Fiorazzo, A., see Turrina, C. (65) 45
Frank, E., see Dew, M.A. (65) 155
Friedman, R.A., see Koran, L.M. (65) 27
Fujimaki, K., Morinobu, S., Takahashi, J., Yamawaki, S., Kato, N., Kanno, M., Okuyama, N., Kawakatsu, S., Otani, K., Kusumi, I. and Koyama, T.
Nucleotide sequence analysis of the binding site on the inositol 1,4,5-trisphosphate type-1 receptor in bipolar disorder — a negative study (65) 139
Furukawa, T.A., Streiner, D.L. and Young, L.T.
Is antidepressant–benzodiazepine combination therapy clinically more useful?. A meta-analytic study (65) 173

Gavin, C., see Bauer, M.S. (65) 231
Geerlings, S.W., see Beekman, A.T.F. (65) 131
Gelenberg, A.J., see Koran, L.M. (65) 27
Ghaemi, S.N. and Goodwin, F.K.
Gabapentin treatment of the non-refractory bipolar spectrum: an open case series (65) 167
Ghaemi, S.N. and Goodwin, F.K.
Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use (65) 281
Gonzalez Pinto, A., see Elizagarate, E. (65) 55
Goodwin, F.K., see Ghaemi, S.N. (65) 167
Goodwin, F.K., see Ghaemi, S.N. (65) 281
Grandi, S., see Fava, G.A. (65) 185
Gregoire, J., see Demyttenaere, K. (65) 243
Grinsted, P., see Pedersen, S.H. (65) 191
Grof, E., see Alda, M. (65) 117
Grof, P., see Alda, M. (65) 117
Gutierrez, M., see Elizagarate, E. (65) 55

Helenius, H., see Pajulo, M. (65) 9
Hirschfeld, R.M.A., see Koran, L.M. (65) 27
Houck, P.R., see Dew, M.A. (65) 155
Howland, R.H., see Koran, L.M. (65) 27
Hrdina, P.D., see Du, L. (65) 37

Joffe, R.T., see Patelis-Siotis, I. (65) 145

Kalyvoka, A., see Rossi, A. (65) 3
Kanno, M., see Fujimaki, K. (65) 139
Kato, N., see Fujimaki, K. (65) 139
Kawakatsu, S., see Fujimaki, K. (65) 139
Keller, D., see Alda, M. (65) 117
Keller, M.B., see Koran, L.M. (65) 27
Kinnear, C.J., see Niehaus, D.J.H. (65) 61
Kirk, G.F., see Bauer, M.S. (65) 231
Klein, D., see Koran, L.M. (65) 27
Knowles, J.A., see Niehaus, D.J.H. (65) 61
Kocsis, J.H., see Koran, L.M. (65) 27
Koran, L.M., Gelenberg, A.J., Kornstein, S.G., Howland, R.H., Friedman, R.A., DeBattista, C., Klein, D., Kocsis, J.H., Schatzberg, A.F., Thase, M.E., Rush, A.J., Hirschfeld, R.M.A., LaVange, L.M. and Keller, M.B.
Sertraline versus imipramine to prevent relapse in chronic depression (65) 27
Kornstein, S.G., see Koran, L.M. (65) 27
Koyama, T., see Fujimaki, K. (65) 139
Kragh-Sørensen, P., see Pedersen, S.H. (65) 191
Kupfer, D.J., see Dew, M.A. (65) 155
Kuroda, S., see Wada, K. (65) 315
Kusumi, I., see Fujimaki, K. (65) 139

Larsen, D.K., see Cox, B.J. (65) 67
LaVange, L.M., see Koran, L.M. (65) 27
Lund, A., see Riise, T. (65) 297

Manicavasagar, V., Silove, D., Rapee, R., Waters, F. and Momartin, S.
Parent–child concordance for separation anxiety: a clinical study (65) 81
Manier, D.H., Shelton, R.C. and Sulser, F.
Cross-talk between PKA and PKC in human fibroblasts: what are the pharmacotherapeutic implications? (65) 275
Marinangeli, M.G., see Rossi, A. (65) 3
Marriott, M., see Patelis-Siotis, I. (65) 145
Mattia, J., see McDermut, W. (65) 289
Mazumdar, S., see Dew, M.A. (65) 155
McDermut, W., Mattia, J. and Zimmerman, M.
Comorbidity burden and its impact on psychosocial morbidity in depressed outpatients (65) 289
Mesters, P., see Demyttenaere, K. (65) 243
Miotto, P., see Preti, A. (65) 253
Momartin, S., see Manicavasagar, V. (65) 81
Moolman-Smook, J.C., see Niehaus, D.J.H. (65) 61
Morinobu, S., see Fujimaki, K. (65) 139
Müller, M.J., see Schneider, B. (65) 263
Mulsant, B., see Dew, M.A. (65) 155

Niehaus, D.J.H., Kinnear, C.J., Corfield, V.A., Du Toit, P.L., Van Kradenburg, J., Moolman-Smook, J.C., Weyers, J.B., Potgieter, A., Seedat, S., Emsley, R.A., Knowles, J.A., Brink, P.A. and Stein, D.J.
Association between a catechol-*o*-methyltransferase polymorphism and obsessive–compulsive disorder in the Afrikaner population (65) 61

Okuyama, N., see Fujimaki, K. (65) 139
Oldehinkel, A.J., see Van den Berg, M.D. (65) 19
Ormel, J., see Van den Berg, M.D. (65) 19
Otani, K., see Fujimaki, K. (65) 139
Ottolini, F., see Fava, G.A. (65) 185

Pajulo, M., Savonlahti, E., Sourander, A., Helenius, H. and Piha, J.
Antenatal depression, substance dependency and social support (65) 9
Paparrigopoulos, T., Psarros, C., Bergiannaki, J.-D., Varsou, E., Dafni, U. and Stefanis, C.
Melatonin response to clonidine administration in depression: indication of presynaptic α_2-adrenoceptor dysfunction (65) 307
Patelis-Siotis, I., Young, L.T., Robb, J.C., Marriott, M., Bieling, P.J., Cox, L.C. and Joffe, R.T.
Group cognitive behavioral therapy for bipolar disorder: a feasibility and effectiveness study (65) 145

Pedersen, S.H., Stage, K.B., Bertelsen, A., Grinsted, P., Kragh-Sørensen, P. and Sørensen, T.
ICD-10 criteria for depression in general practice (65) 191
Petruzzi, C., see Rossi, A. (65) 3
Philipp, M., see Schneider, B. (65) 263
Piha, J., see Pajulo, M. (65) 9
Potgieter, A., see Niehaus, D.J.H. (65) 61
Preti, A. and Miotto, P.
Diurnal variations in suicide by age and gender in Italy (65) 253
Psarros, C., see Paparrigopoulos, T. (65) 307
Pz de Heredia, J.L., see Elizagarate, E. (65) 55

Rafanelli, C., see Fava, G.A. (65) 185
Rajan Thomas, N., see Sherwood Brown, E. (65) 105
Ramirez, M., see Elizagarate, E. (65) 55
Rapee, R., see Manicavasagar, V. (65) 81
Regini, C., see Turrina, C. (65) 45
Reynolds, C.F., see Dew, M.A. (65) 155
Riise, T. and Lund, A.
Prognostic factors in major depression: A long-term follow-up study of 323 patients (65) 297
Robb, J.C., see Patelis-Siotis, I. (65) 145
Rohde, P.
The relevance of hierarchies, territories, defeat for depression in humans: hypotheses and clinical predictions (65) 221
Rossi, A., Marinangeli, M.G., Butti, G., Scinto, A., Di Cicco, L., Kalyvoka, A. and Petruzzi, C.
Personality disorders in bipolar and depressive disorders (65) 3
Rouleau, G.A., see Alda, M. (65) 117
Ruini, C., see Fava, G.A. (65) 185
Rush, A.J., see Koran, L.M. (65) 27

Sacchetti, E., see Turrina, C. (65) 45
Sanger, T., see Tohen, M. (65) 85
Savonlahti, E., see Pajulo, M. (65) 9
Schatzberg, A.F., see Koran, L.M. (65) 27
Schneider, B., Müller, M.J. and Philipp, M.
Mortality in affective disorders (65) 263
Schoevers, R.A., see Beekman, A.T.F. (65) 131
Scinto, A., see Rossi, A. (65) 3
Seedat, S., see Niehaus, D.J.H. (65) 61
Shelton, R.C., see Manier, D.H. (65) 275
Sher, L.
Relationship between mood disorders and coronary artery disease: possible role of the immune system and infection (65) 195
Sherwood Brown, E., Suppes, T., Adinoff, B. and Rajan Thomas, N.
Drug abuse and bipolar disorder: comorbidity or misdiagnosis? (65) 105
Silove, D., see Manicavasagar, V. (65) 81
Smit, J.H., see Beekman, A.T.F. (65) 131
Sørensen, T., see Pedersen, S.H. (65) 191
Sourander, A., see Pajulo, M. (65) 9
Stage, K.B., see Pedersen, S.H. (65) 191
Stefanis, C., see Paparrigopoulos, T. (65) 307
Stein, D.J., see Niehaus, D.J.H. (65) 61
Stewart, J.W., see Agosti, V. (65) 75
Streiner, D.L., see Furukawa, T.A. (65) 173
Sulser, F., see Manier, D.H. (65) 275
Suppes, T., see Sherwood Brown, E. (65) 105

Takahashi, J., see Fujimaki, K. (65) 139
Taylor, C.C., see Tohen, M. (65) 85
Thase, M.E., see Koran, L.M. (65) 27
Thiruvengadam, A.
Effect of lithium and sodium valproate ions on resting membrane potentials in neurons: an hypothesis (65) 95
Tohen, M., Zhang, F., Taylor, C.C., Burns, P., Zarate, C., Sanger, T. and Tollefson, G.
A meta-analysis of the use of typical antipsychotic agents in bipolar disorder (65) 85
Tollefson, G., see Tohen, M. (65) 85
Turano, A., see Turrina, C. (65) 45
Turecki, G., see Alda, M. (65) 117
Turrina, C., Fiorazzo, A., Turano, A., Cacciani, P., Regini, C., Castelli, F. and Sacchetti, E.
Depressive disorders and personality variables in HIV positive and negative intravenous drug-users (65) 45

Van den Berg, M.D., Oldehinkel, A.J., Bouhuys, A.L., Brilman, E.I., Beekman, A.T.F. and Ormel, J.
Depression in later life: three etiologically different subgroups (65) 19
Van Ganse, E., see Demyttenaere, K. (65) 243
van Kradenburg, J., see Niehaus, D.J.H. (65) 61
van Tilburg, W., see Beekman, A.T.F. (65) 131
van Vliet, I.M., see Dingemans, A.E. (65) 123
Varsou, E., see Paparrigopoulos, T. (65) 307

Wada, K., Yamada, N., Yamauchi, Y. and Kuroda, S.
Carbamazepine treatment of corticosteroid-induced mood disorder (65) 315
Waters, F., see Manicavasagar, V. (65) 81
Westenberg, H.G., see Dingemans, A.E. (65) 123
Weyers, J.B., see Niehaus, D.J.H. (65) 61
Williford, W.O., see Bauer, M.S. (65) 231

Yamada, N., see Wada, K. (65) 315
Yamauchi, Y., see Wada, K. (65) 315
Yamawaki, S., see Fujimaki, K. (65) 139
Young, L.T., see Alda, M. (65) 117
Young, L.T., see Furukawa, T.A. (65) 173
Young, L.T., see Patelis-Siotis, I. (65) 145

Zarate, C., see Tohen, M. (65) 85
Zhang, F., see Tohen, M. (65) 85
Zimmerman, M., see McDermut, W. (65) 289

ELSEVIER

Journal of Affective Disorders 65 (2001) 327–330

JOURNAL OF AFFECTIVE DISORDERS

www.elsevier.com/locate/jad

Subject index

Activities of daily living; Bipolar disorder; Outcome assessment (healthcare); Direct service costs; Functional status; Child abuse **65,** 231

ADHD; Mania; Executive functions; Evolution; Fitness; Natural selection; Domain specificity **65,** 197

Adolescence; Suicide; Mood disorders; Circadian rhythm; Serotonin; Social factors; Age **65,** 253

Age; Suicide; Mood disorders; Circadian rhythm; Serotonin; Social factors; Adolescence **65,** 253

Agoraphobia; Panic disorder; Well-being; Residual symptoms; Behavioral therapy **65,** 185

Amitriptyline; Depressed patients; Fluoxetine **65,** 243

Analogue depression; Depression; Cluster analysis **65,** 67

Antidepressants; Major depression; Drug Therapy; Benzodiazepines **65,** 173

Antimanic properties; Bipolar disorder; Typical antipsychotics **65,** 85

Anxiety disorders; Concordance studies; Family studies; Separation anxiety **65,** 81

Atypical depression; Social functioning; Chronic depression **65,** 75

Atypical depression; Hypomania; Mixed state; Bipolar II **65,** 179

α_2-Adrenoceptors; Melatonin; Clonidine; Depression **65,** 307

Behavioral therapy; Panic disorder; Agoraphobia; Well-being; Residual symptoms **65,** 185

Benzodiazepines; Major depression; Drug Therapy; Antidepressants **65,** 173

Biological marker; Bipolar disorder; Lithium; G protein; Signal transduction **65,** 117

Bipolar disorder; Typical antipsychotics; Antimanic properties **65,** 85

Bipolar disorder; Substance abuse; Mood stabilizers; Neuroleptics **65,** 105

Bipolar disorder; Lithium; G protein; Signal transduction; Biological marker **65,** 117

Bipolar disorder; Inositol 1,4,5-trisphosphate receptor; Calcium; Calcineurin; FKBP-12 **65,** 139

Bipolar disorder; Cognitive behavior therapy; Group treatment; Psychosocial functioning **65,** 145

Bipolar disorder; Drug therapy; Gabapentin; Mood disorders; Depression **65,** 167

Bipolar disorder; Outcome assessment (healthcare); Direct service costs; Functional status; Activities of daily living; Child abuse **65,** 231

Bipolar disorder; Drug therapy; Valproate; Divalproex sodium; Valproic acid; Lithium carbonate; Outcome; Side effects; Treatment resistance; Depression **65,** 281

Bipolar II; Atypical depression; Hypomania; Mixed state **65,** 179

Calcineurin; Bipolar disorder; Inositol 1,4,5-trisphosphate receptor; Calcium; FKBP-12 **65,** 139

Calcium; Bipolar disorder; Inositol 1,4,5-trisphosphate receptor; Calcineurin; FKBP-12 **65,** 139

Catechol-*O*-methyl transferase; Obsessive–compulsive disorder; Genetics **65,** 61

Cerebral blood flow; SPECT; Electroconvulsive therapy: Depression **65,** 55

Child abuse; Bipolar disorder; Outcome assessment (healthcare); Direct service costs; Functional status; Activities of daily living **65,** 231

Childhood; Major depressive disorder; Predictive factors; Social factors; Occupation **65,** 297

Chronic depression; Dysthymia; Sertraline; Imipramine; Continuation phase treatment **65,** 27

Chronic depression; Atypical depression; Social functioning **65,** 75

Circadian rhythm; Suicide; Mood disorders; Serotonin; Social factors; Age; Adolescence **65,** 253

Clonidine; Melatonin; Depression; α_2-Adrenoceptors **65,** 307

Cluster analysis; Depression; Analogue depression **65,** 67

PII: S0165-0327(01)00382-2

Cognitive behavior therapy; Bipolar disorder; Group treatment; Psychosocial functioning **65,** 145

Comorbidity; Mood disorders; Personality disorders; SCID-II **65,** 3

Comorbidity; Depression; Psychosocial functioning **65,** 289

Concordance studies; Anxiety disorders; Family studies; Separation anxiety **65,** 81

Consciousness; Evolution; Hierarchy; Social competition; Defeat; Depression **65,** 221

Continuation phase treatment; Chronic depression; Dysthymia; Sertraline; Imipramine **65,** 27

Defeat; Evolution; Hierarchy; Social competition; Depression; Consciousness **65,** 221

Depressed patients; Amitriptyline; Fluoxetine **65,** 243

Depression; Pregnancy; Substance dependency; Social support **65,** 9

Depression; Early-onset; Late-onset; Vulnerability; Vascular depression **65,** 19

Depression; Tryptophan hydroxylase gene; Somatic anxiety; Polymorphism; Serotonin **65,** 37

Depression; HIV; Intravenous drug user; Personality **65,** 45

Depression; Analogue depression; Cluster analysis **65,** 67

Depression; Bipolar disorder; Drug therapy; Gabapentin; Mood disorders **65,** 167

Depression; Evolution; Hierarchy; Social competition; Defeat; Consciousness **65,** 221

Depression; Bipolar disorder; Drug therapy; Valproate; Divalproex sodium; Valproic acid; Lithium carbonate; Outcome; Side effects; Treatment resistance **65,** 281

Depression; Comorbidity; Psychosocial functioning **65,** 289

Depression; Melatonin; Clonidine; α_2-Adrenoceptors **65,** 307

Direct service costs; Bipolar disorder; Outcome assessment (healthcare); Functional status; Activities of daily living; Child abuse **65,** 231

Divalproex sodium; Bipolar disorder; Drug therapy; Valproate; Valproic acid; Lithium carbonate; Outcome; Side effects; Treatment resistance; Depression **65,** 281

Domain specificity; ADHD; Mania; Executive functions; Evolution; Fitness; Natural selection **65,** 197

Drug therapy; Bipolar disorder; Gabapentin; Mood disorders; Depression **65,** 167

Drug Therapy; Major depression; Antidepressants; Benzodiazepines **65,** 173

Drug therapy; Bipolar disorder; Valproate; Divalproex sodium; Valproic acid; Lithium carbonate; Outcome; Side effects; Treatment resistance; Depression **65,** 281

Dysthymia; Chronic depression; Sertraline; Imipramine; Continuation phase treatment **65,** 27

Early-onset; Depression; Late-onset; Vulnerability; Vascular depression **65,** 19

Electroconvulsive therapy: Depression; SPECT; Cerebral blood flow **65,** 55

Epidemiology; Social phobia; Phobic-disorders-therapy; Treatment-outcome **65,** 123

Evolution; ADHD; Mania; Executive functions; Fitness; Natural selection; Domain specificity **65,** 197

Evolution; Hierarchy; Social competition; Defeat; Depression; Consciousness **65,** 221

Executive functions; ADHD; Mania; Evolution; Fitness; Natural selection; Domain specificity **65,** 197

Family studies; Anxiety disorders; Concordance studies; Separation anxiety **65,** 81

Fitness; ADHD; Mania; Executive functions; Evolution; Natural selection; Domain specificity **65,** 197

FKBP-12; Bipolar disorder; Inositol 1,4,5-trisphosphate receptor; Calcium; Calcineurin **65,** 139

Fluoxetine; Depressed patients; Amitriptyline **65,** 243

Functional status; Bipolar disorder; Outcome assessment (healthcare); Direct service costs; Activities of daily living; Child abuse **65,** 231

G protein; Bipolar disorder; Lithium; Signal transduction; Biological marker **65,** 117

Gabapentin; Bipolar disorder; Drug therapy; Mood disorders; Depression **65,** 167

Genetics; Catechol-*O*-methyl transferase; Obsessive–compulsive disorder **65,** 61

Group treatment; Bipolar disorder; Cognitive behavior therapy; Psychosocial functioning **65,** 145

Hierarchy; Evolution; Social competition; Defeat; Depression; Consciousness **65,** 221

HIV; Intravenous drug user; Depression; Personality **65,** 45

Human fibroblasts; Protein kinase A (PKA); Protein kinase C (PKC); Nuclear CREB phosphorylation (CREB-P) **65,** 275

Hypomania; Atypical depression; Mixed state; Bipolar II **65,** 179

Imipramine; Chronic depression; Dysthymia; Sertraline; Continuation phase treatment **65,** 27

Inositol 1,4,5-trisphosphate receptor; Bipolar disorder; Calcium; Calcineurin; FKBP-12 **65,** 139

Interpersonal psychotherapy; Major depression; Older adults; Treatment response profiles; Maintenance therapies; Nortriptyline **65,** 155

Intravenous drug user; HIV; Depression; Personality **65,** 45

Late life depression; Longitudinal Aging Study Amsterdam; Onset; Prevalence; Persistence; Risk factors **65,** 131

Late-onset; Depression; Early-onset; Vulnerability; Vascular depression **65,** 19

Lithium; Manic depression; Sodium valproate; Resting membrane potentials **65,** 95

Lithium; Bipolar disorder; G protein; Signal transduction; Biological marker **65,** 117

Lithium carbonate; Bipolar disorder; Drug therapy; Valproate; Divalproex sodium; Valproic acid; Outcome; Side effects; Treatment resistance; Depression **65,** 281

Longitudinal Aging Study Amsterdam; Late life depression; Onset; Prevalence; Persistence; Risk factors **65,** 131

Maintenance therapies; Major depression; Older adults; Treatment response profiles; Nortriptyline; Interpersonal psychotherapy **65,** 155

Major depression; Older adults; Treatment response profiles; Maintenance therapies; Nortriptyline; Interpersonal psychotherapy **65,** 155

Major depression; Drug Therapy; Antidepressants; Benzodiazepines **65,** 173

Major depressive disorder; Predictive factors; Childhood; Social factors; Occupation **65,** 297

Mania; ADHD; Executive functions; Evolution; Fitness; Natural selection; Domain specificity **65,** 197

Manic depression; Lithium; Sodium valproate; Resting membrane potentials **65,** 95

Melatonin; Clonidine; Depression; α_2-Adrenoceptors **65,** 307

Mixed state; Atypical depression; Hypomania; Bipolar II **65,** 179

Mood disorders; Personality disorders; SCID-II; Comorbidity **65,** 3

Mood disorders; Bipolar disorder; Drug therapy; Gabapentin; Depression **65,** 167

Mood disorders; Suicide; Circadian rhythm; Serotonin; Social factors; Age; Adolescence **65,** 253

Mood stabilizers; Bipolar disorder; Substance abuse; Neuroleptics **65,** 105

Natural death; Over-mortality; Unnatural death; Subtypes of affective disorders; Social–demographic features **65,** 263

Natural selection; ADHD; Mania; Executive functions; Evolution; Fitness; Domain specificity **65,** 197

Neuroleptics; Bipolar disorder; Substance abuse; Mood stabilizers **65,** 105

Nortriptyline; Major depression; Older adults; Treatment response profiles; Maintenance therapies; Interpersonal psychotherapy **65,** 155

Nuclear CREB phosphorylation (CREB-P); Human fibroblasts; Protein kinase A (PKA); Protein kinase C (PKC) **65,** 275

Obsessive–compulsive disorder; Catechol-*O*-methyl transferase; Genetics **65,** 61

Occupation; Major depressive disorder; Predictive factors; Childhood; Social factors **65,** 297

Older adults; Major depression; Treatment response profiles; Maintenance therapies; Nortriptyline; Interpersonal psychotherapy **65,** 155

Onset; Late life depression; Longitudinal Aging Study Amsterdam; Prevalence; Persistence; Risk factors **65,** 131

Outcome; Bipolar disorder; Drug therapy; Valproate; Divalproex sodium; Valproic acid; Lithium carbonate; Side effects; Treatment resistance; Depression **65,** 281

Outcome assessment (healthcare); Bipolar disorder; Direct service costs; Functional status; Activities of daily living; Child abuse **65,** 231

Over-mortality; Unnatural death; Natural death; Subtypes of affective disorders; Social–demographic features **65,** 263

Panic disorder; Agoraphobia; Well-being; Residual symptoms; Behavioral therapy **65,** 185

Persistence; Late life depression; Longitudinal Aging Study Amsterdam; Onset; Prevalence; Risk factors **65,** 131

Personality; HIV; Intravenous drug user; Depression **65,** 45

Personality disorders; Mood disorders; SCID-II; Comorbidity **65,** 3

Phobic-disorders-therapy; Social phobia; Epidemiology; Treatment-outcome **65,** 123

Polymorphism; Tryptophan hydroxylase gene; Somatic anxiety; Depression; Serotonin **65,** 37

Predictive factors; Major depressive disorder; Childhood; Social factors; Occupation **65,** 297

Pregnancy; Depression; Substance dependency; Social support **65,** 9

Prevalence; Late life depression; Longitudinal Aging Study Amsterdam; Onset; Persistence; Risk factors **65,** 131

Protein kinase A (PKA); Human fibroblasts; Protein kinase C (PKC); Nuclear CREB phosphorylation (CREB-P) **65,** 275

Protein kinase C (PKC); Human fibroblasts; Protein kinase A (PKA); Nuclear CREB phosphorylation (CREB-P) **65,** 275

Psychosocial functioning; Bipolar disorder; Cognitive behavior therapy; Group treatment **65,** 145

Psychosocial functioning; Depression; Comorbidity **65,** 289

Residual symptoms; Panic disorder; Agoraphobia; Well-being; Behavioral therapy **65,** 185

Resting membrane potentials; Manic depression; Lithium; Sodium valproate **65,** 95

Risk factors; Late life depression; Longitudinal Aging Study Amsterdam; Onset; Prevalence; Persistence **65,** 131

SCID-II; Mood disorders; Personality disorders; Comorbidity **65,** 3

Separation anxiety; Anxiety disorders; Concordance studies; Family studies **65,** 81

Serotonin; Tryptophan hydroxylase gene; Somatic anxiety; Depression; Polymorphism **65,** 37

Serotonin; Suicide; Mood disorders; Circadian rhythm; Social factors; Age; Adolescence **65,** 253

Sertraline; Chronic depression; Dysthymia; Imipramine; Continuation phase treatment **65,** 27

Side effects; Bipolar disorder; Drug therapy; Valproate; Divalproex sodium; Valproic acid; Lithium carbonate; Outcome; Treatment resistance; Depression **65,** 281

Signal transduction; Bipolar disorder; Lithium; G protein; Biological marker **65,** 117

Social competition; Evolution; Hierarchy; Defeat; Depression; Consciousness **65,** 221

Social factors; Suicide; Mood disorders; Circadian rhythm; Serotonin; Age; Adolescence **65,** 253

Social factors; Major depressive disorder; Predictive factors; Childhood; Occupation **65,** 297

Social functioning; Atypical depression; Chronic depression **65,** 75

Social phobia; Epidemiology; Phobic-disorders-therapy; Treatment-outcome **65,** 123

Social support; Depression; Pregnancy; Substance dependency **65,** 9

Social–demographic features; Over-mortality; Unnatural death; Natural death; Subtypes of affective disorders **65,** 263

Sodium valproate; Manic depression; Lithium; Resting membrane potentials **65,** 95

Somatic anxiety; Tryptophan hydroxylase gene; Depression; Polymorphism; Serotonin **65,** 37

SPECT; Electroconvulsive therapy: Depression; Cerebral blood flow **65,** 55

Substance abuse; Bipolar disorder; Mood stabilizers; Neuroleptics **65,** 105

Substance dependency; Depression; Pregnancy; Social support **65,** 9

Subtypes of affective disorders; Over-mortality; Unnatural death; Natural death; Social–demographic features **65,** 263

Suicide; Mood disorders; Circadian rhythm; Serotonin; Social factors; Age; Adolescence **65,** 253

Treatment resistance; Bipolar disorder; Drug therapy; Valproate; Divalproex sodium; Valproic acid; Lithium carbonate; Outcome; Side effects; Depression **65,** 281

Treatment response profiles; Major depression; Older adults; Maintenance therapies; Nortriptyline; Interpersonal psychotherapy **65,** 155

Treatment-outcome; Social phobia; Epidemiology; Phobic-disorders-therapy **65,** 123

Tryptophan hydroxylase gene; Somatic anxiety; Depression; Polymorphism; Serotonin **65,** 37

Typical antipsychotics; Bipolar disorder; Antimanic properties **65,** 85

Unnatural death; Over-mortality; Natural death; Subtypes of affective disorders; Social–demographic features **65,** 263

Valproate; Bipolar disorder; Drug therapy; Divalproex sodium; Valproic acid; Lithium carbonate; Outcome; Side effects; Treatment resistance; Depression **65,** 281

Valproic acid; Bipolar disorder; Drug therapy; Valproate; Divalproex sodium; Lithium carbonate; Outcome; Side effects; Treatment resistance; Depression **65,** 281

Vascular depression; Depression; Early-onset; Late-onset; Vulnerability **65,** 19

Vulnerability; Depression; Early-onset; Late-onset; Vascular depression **65,** 19

Well-being; Panic disorder; Agoraphobia; Residual symptoms; Behavioral therapy **65,** 185